European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Go back to European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status| Gilead Sciences (NASDAQ: GILD) | Delayed: 143.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.72 | 52 Week High | $108.63 | |||
| Open | $143.72 | 52 Week Low | $71.39 | |||
| Day High | $143.72 | P/E | 79.40 | |||
| Day Low | $143.72 | EPS | $1.81 | |||
| Volume | 81,652 | |||||
